Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Revisit the Top Presentations and Biggest Data From the 2025 @ascocancer.bsky.social Gastrointestinal Cancers Symposium #GI25 #crcsm #HCC #pansm www.onclive.com/view/revisit...

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC #GI25 #pansm #oncology www.onclive.com/view/ras-on-...

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC #pansm #oncology
www.onclive.com/view/ema-gra...

FDA grants accelerated approval to zenocutuzumab-zbco On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

The HER2:HER3 bispecific Ab #zenocutuzumab was #FDAapproved for advanced, unresectable, or metastatic NRG1 fusion+ NSCLC (ORR 33%; mDOR 7.4 mo) and NRG1 fusion+ pancreatic adenocarcinoma (ORR 40%; DOR 3.7-16.6 mo) after 1 systemic Tx #lcsm #pancan #oncsky #cansky #pansm bit.ly/41lRFwW @fda.gov